

THE UNIVERSITY OF MICHIGAN

REGENTS COMMUNICATION

ACTION REQUEST

EXH	MOTION <i>Newman</i>
	SECOND <i>Maynard</i>
	ACTION APPROVED BY THE REGENTS
NOTE: SEP 15 2005	
University of Michigan	

Subject: Research Agreement between the University of Michigan and Pipex, Inc.

Action Requested: Authorization to enter into Agreement

Preamble:

A statutory conflict of interest situation was identified by the Division of Research Development and Administration while reviewing the Proposal Approval Form which then triggered a review by the Medical School Conflict of Interest Board. A plan for management of the possible risks associated with the conflict of interest was then developed by this Board and agreed to by the parties involved in this agreement.

This proposed research agreement ("Agreement") falls under the State of Michigan Conflict of Interest Statute because Professor George Brewer is both an employee of the University of Michigan ("University") and a partial owner of, Chair of the Scientific Advisory Board of and consultant to Pipex, Inc. ("Pipex"). The law permits such an Agreement provided it is disclosed to the executive officers and approved in advance by a 2/3 vote of the Regents of the University of Michigan.

Background:

Dr. Brewer, a Professor Emeritus in Human Genetics, is the partial owner of, Chair of the Scientific Advisory Board of and consultant to a for-profit company called Pipex. Pipex now wishes to contract with the University in order to conduct research. The Principal Investigator for this project is Dr. George Brewer. Dr. Brewer will only participate in this project in his capacity as a University employee.

Nature of the Agreement:

The Company wishes to contract to the University to assist with the development of antifibrotic and antiinflammatory studies of ammonium tetrathiomolybdate.

Agreement Terms:

Under this Agreement, a total of \$1,378,500.00 is anticipated to cover the period June 1, 2005 though May 31, 2008. Since research agreements are often amended, the Agreement includes provisions for changes in time, amount, and scope. University procedures for approval of these changes will be followed and additional review by the Medical School Conflict of Interest Board will be done as appropriate.


Impact of the Agreement:

The Agreement will support the continued effort by Dr. Brewer to perform antifibrotic and antiinflammatory studies of ammonium tetrathiomolybdate.

Recommendations:

This matter has been reviewed and approved by the Medical School Conflict of Interest Board. In light of this disclosure and our finding that the Agreement was negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the Research Agreement between the University and Pipex, Inc.

Respectfully Submitted,



Fawwaz T. Ulaby
Vice President for Research

September 2005